{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T23:37:32Z","timestamp":1773272252120,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"42","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,23]],"date-time":"2017-08-23T00:00:00Z","timestamp":1503446400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.vaccine.2017.08.048","type":"journal-article","created":{"date-parts":[[2017,9,8]],"date-time":"2017-09-08T08:47:14Z","timestamp":1504860434000},"page":"5674-5681","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Evaluating cessation of the type 2 oral polio vaccine by modeling pre- and post-cessation detection rates"],"prefix":"10.1016","volume":"35","author":[{"given":"Steve J.","family":"Kroiss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Famulare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hil","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin A.","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laina D.","family":"Mercer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Chabot-Couture","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.08.048_b0005","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/oxfordjournals.aje.a009924","article-title":"Transmissibility and persistence of oral polio vaccine viruses: implications for the global poliomyelitis eradication initiative","volume":"150","author":"Fine","year":"1999","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2017.08.048_b0010","series-title":"Vaccines","first-page":"598","article-title":"Poliovirus vaccine-live","author":"Sutter","year":"2013"},{"key":"10.1016\/j.vaccine.2017.08.048_b0015","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1586\/14760584.2016.1140041","article-title":"Polio endgame: the global switch from tOPV to bOPV","volume":"15","author":"Garon","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2017.08.048_b0020","first-page":"358","article-title":"Factors associated with missed vaccination during mass immunization campaigns","volume":"27","author":"Weiss","year":"2009","journal-title":"J Heal Popul Nutr"},{"issue":"Suppl","key":"10.1016\/j.vaccine.2017.08.048_b0025","doi-asserted-by":"crossref","first-page":"S176","DOI":"10.1093\/infdis\/175.Supplement_1.S176","article-title":"Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance: a review of the literature","volume":"175","author":"Alexander","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.08.048_b0030","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/ije\/dyg185","article-title":"Poliovirus detection in wastewater and stools following an immunization campaign in Havana, Cuba","volume":"32","author":"Lago","year":"2003","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.vaccine.2017.08.048_b0035","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1128\/AEM.07972-11","article-title":"Feasibility of quantitative environmental surveillance in poliovirus eradication strategies","volume":"78","author":"Lodder","year":"2012","journal-title":"Appl Environ Microbiol"},{"key":"10.1016\/j.vaccine.2017.08.048_b0040","doi-asserted-by":"crossref","first-page":"S347","DOI":"10.1093\/infdis\/jiu060","article-title":"Switch from oral to inactivated poliovirus vaccine in Yogyakarta province, Indonesia: summary of coverage, immunity, and environmental surveillance","volume":"210","author":"Wahjuhono","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.08.048_b0045","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1136\/bmj.1.5280.743","article-title":"Enterovirus survey in children after mass vaccination with live attenuated polioviruses","volume":"1","author":"Domok","year":"1962","journal-title":"Br Med J"},{"key":"10.1016\/j.vaccine.2017.08.048_b0050","first-page":"1091","article-title":"Mass oral (Sabin) poliomyelitis vaccination in Czechoslovakia, 1958\u20139 and 1960","volume":"1","author":"\u017d\u00e1\u010dek","year":"1962","journal-title":"Br Med J"},{"key":"10.1016\/j.vaccine.2017.08.048_b0055","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(86)91566-7","article-title":"Outbreak of paralytic poliomyelitis in Finland: widespread circulation of antigenically altered poliovirus type 3 in a vaccinated population","volume":"327","author":"Hovi","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.08.048_b0060","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1128\/AEM.54.2.371-374.1988","article-title":"Viruses in sewage waters during and after a poliomyelitis outbreak and subsequent nationwide oral poliovirus vaccination campaign in Finland","volume":"54","author":"Poyry","year":"1988","journal-title":"Appl Environ Microbiol"},{"key":"10.1016\/j.vaccine.2017.08.048_b0065","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0140-6736(05)66386-6","article-title":"Persistence of oral polio vaccine virus after its removal from the immunisation schedule in New Zealand","volume":"366","author":"Huang","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.08.048_b0070","first-page":"196","article-title":"Live, orally given poliovirus vaccine. Effects of rapid mass immunization on population under conditions of massive enteric infection with other viruses. 1960","volume":"77","author":"Sabin","year":"1999","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2017.08.048_b0075","first-page":"221","article-title":"Lessons from Cuba: mass campaign administration of trivalent oral poliovirus vaccine and seroprevalence of poliovirus neutralizing antibodies","volume":"72","author":"Mas Lago","year":"1994","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2017.08.048_b0080","doi-asserted-by":"crossref","first-page":"346","DOI":"10.15585\/mmwr.mm6513a3","article-title":"Surveillance systems to track progress toward polio eradication \u2013 worldwide, 2014\u20132015","volume":"65","author":"Snider","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2017.08.048_b0085","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/oxfordjournals.epirev.a018041","article-title":"Differential diagnosis of acute flaccid paralysis and its role in poliomyelitis surveillance","volume":"22","author":"Marx","year":"2000","journal-title":"Epidemiol Rev"},{"key":"10.1016\/j.vaccine.2017.08.048_b0090","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(12)60648-5","article-title":"The effect of mass immunisation campaigns and new oral poliovirus vaccines on the incidence of poliomyelitis in Pakistan and Afghanistan, 2001\u201311: a retrospective analysis","volume":"380","author":"O\u2019Reilly","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.08.048_b0095","doi-asserted-by":"crossref","first-page":"S283","DOI":"10.1093\/infdis\/jiu295","article-title":"Vaccine-derived polioviruses","volume":"210","author":"Burns","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.08.048_b0100","unstructured":"Stan Development Team. RStan: the R interface to Stan; 2016."},{"key":"10.1016\/j.vaccine.2017.08.048_b0105","unstructured":"R Core Team. R: A language and environment for statistical computing; 2016."},{"key":"10.1016\/j.vaccine.2017.08.048_b0110","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/S0140-6736(07)60531-5","article-title":"Protective efficacy of a monovalent oral type 1 poliovirus vaccine: a case-control study","volume":"369","author":"Grassly","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.08.048_b0115","doi-asserted-by":"crossref","unstructured":"Fox JP, Gelfand HM, LeBlanc DR, Potash L, Clemmer DI, LaPenta D. The spread of vaccine strains of poliovirus in the household and in the community in southern Louisiana. In: Lippincott, editor. Polio. Pap. Discuss. Present. fifth Int. Polio. Conf., Philadelphia; 1961, p. 368\u2013383.","DOI":"10.1097\/00006199-196101010-00038"},{"key":"10.1016\/j.vaccine.2017.08.048_b0120","first-page":"128","article-title":"Effects of rapid mass immunization of a population with live, oral poliovirus vaccine under conditions of massive enteric infection with other viruses","volume":"73","author":"Sabin","year":"1960","journal-title":"Trans Assoc Am Physicians"},{"key":"10.1016\/j.vaccine.2017.08.048_b0125","doi-asserted-by":"crossref","unstructured":"Chen RT, Hausinger S, Dajani A, Hanfling M, Baughman A, Pallansch M, et al. Seroprevalence of antibody against poliovirus in inner-city preschool children. Implications for vaccination policy in the United States. JAMA 1996;275:1639\u20131645. http:\/\/dx.doi.org\/10.1001\/jama.275.21.1639.","DOI":"10.1001\/jama.275.21.1639"},{"issue":"Suppl","key":"10.1016\/j.vaccine.2017.08.048_b0130","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1093\/infdis\/175.Supplement_1.S86","article-title":"Unimmunized Gypsy populations and implications for the eradication of poliomyelitis in Europe","volume":"175","author":"Aylward","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.08.048_b0135","doi-asserted-by":"crossref","first-page":"538","DOI":"10.15585\/mmwr.mm6620a4","article-title":"Virologic monitoring of poliovirus type 2 after oral poliovirus vaccine type 2 withdrawal in April 2016 \u2013 Worldwide, 2016\u20132017","volume":"66","author":"Diop","year":"2017","journal-title":"Morb Mortrality Wkly Rep"},{"key":"10.1016\/j.vaccine.2017.08.048_b0140","doi-asserted-by":"crossref","first-page":"770","DOI":"10.15585\/mmwr.mm6530a4","article-title":"Environmental isolation of circulating vaccine-derived poliovirus after interruption of wild poliovirus transmission \u2013 Nigeria, 2016","volume":"65","author":"Etsano","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2017.08.048_b0145","article-title":"Sabin vaccine reversion in the field: a comprehensive analysis of Sabin-like poliovirus isolates in Nigeria","volume":"90","author":"Famulare","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.08.048_b0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S095026881000316X","article-title":"Role of environmental poliovirus surveillance in global polio eradication and beyond","volume":"140","author":"Hovi","year":"2012","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2017.08.048_b0155","first-page":"398","article-title":"Circulating vaccine-derived poliovirus and its implications for polio surveillance and eradication in Nigeria: a review of the literature","volume":"4","author":"Okonko","year":"2009","journal-title":"Sci Res Essays"},{"key":"10.1016\/j.vaccine.2017.08.048_b0160","unstructured":"World Health Organization. WHO vaccine-preventable diseases monitoring system: 2015 global summary 2016. http:\/\/apps.who.int\/immunization_monitoring\/globalsummary (accessed October 19, 2016)."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17311362?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17311362?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T13:32:20Z","timestamp":1659447140000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17311362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":32,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0264410X17311362"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.08.048","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating cessation of the type 2 oral polio vaccine by modeling pre- and post-cessation detection rates","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.08.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}